Abstract library

17 results for "Rego".
#49 Twenty-year experience in diagnosis and treatment of insulinoma in Burdenko Surgery Clinic, Moscow Medical Academy, Russia
Introduction: For the last 20 years, 235 patients with the diagnosis of organic hyperinsulinismus were treated in Burdenko Surgery Clinic.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Prof Alexey Egorov
#50 Clinical-morphology correlation in diagnostics and evaluating surgery results of pancreatic insulinoma and nesidiobastosis
Introduction: Organic hyperinsulinism syndrome (OHS) is revealed in 85% cases of pancreas insulinoma. Nesidioblastosis (NB) induces OHS in 15% of the cases. Surgical cure provides all symptoms of insulinoma disappearing, while cytoreductive operation results in considerable improvement of life quality. There is no intraoperative opportunity to reveal insulinoma grade, even if an urgent biopsy is performed. Thus, it is essential to determine the cause of OHS and to apply the surgical cure method during the preoperational period, thereby improving the long-term prognosis.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr. Evelina Askenderova
#61 Multiple tumors in patients with pancreatic neuroendocrine tumours: morphological and immunohistochemical characteristics
Introduction: Pancreatic islet cell tumors occur in 80% of patients with MEN 1. Tumors are often multicentric. They often produce multiple peptides and biogenic amines.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Prof Larisa Gurevich
#221 Diagnostic Algorithm of Pancreatic Neuroendocrine Tumors
Introduction: Diagnostics of pNETs is associated with certain problems due to a variety of clinical features, including a rather small size of primaries and, quite often, multiple lesions.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Ivan A Vasiliev
#223 Management of Patients with Multiple Pancreatic Tumors
Introduction: MEN-1 syndrome is a rather rare disease. It is very complicated to manage this group of patients because of the multiple pancreatic lesions and high frequency of nesidioblastosis.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Ivan Vasiliev
#239 CK 19 Expression in Pancreatic Neuroendocrine Tumors as Negative Prognostic Factor and a Risk Factor for Metastases
Introduction: Neuroendocrine tumors (NET) of the pancreas are slow growing neoplasms, but they can metastasize after many years after surgery.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Larisa Gurevich
#348 Management of Multiple Endocrine Neoplasia Type 1 in Patients with Pancreatic Neuroendocrine Tumors
Introduction: Screening for MEN-1 is an integral part of examination of patients with pNETs because revelation of this hereditary pathology radically influences tactics of treatment.
Conference:
Category: Basic
Presenting Author: Ivan Vasiliev
#419 Morphological Characteristics of Pancreatic Tumors in Children and Young Patients
Introduction: Pancreatic tumors (PT) usually occur after age 60 and almost never in children and young patients (pts). Little is known concerning frequency, morphological and immunohistochemical (IHC) characteristics of PTs in children and young pts.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: I Voronkova
#546 Treatment of Malignant Neuroendocrine Tumors of the Hepatopancreatododenal Region
Introduction: The incidence of malignant NETs of the hepatopancreatoduodenal region is currently set at 10-15 cases per 100,000 people. Patient treatment and prognosis differ from those with adenocarcinoma.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Ivan Vasiliev
#689 Immunohistochemical Expression of Somatostatin Receptors 1, 2, 3, and 5 Types (SSR) in Functioning and Non-Functioning Gastroenteropancreatic Neuroendocrine Tumors
Introduction: SSRs are therapeutic targets for the somatostatin analogues in treatment of gasrtroenteropancreatic neuroendocrine tumors (GEP-NET).
Conference: 10th Annual ENETS Conference (2013)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: MD Larisa Gurevich